PlasmaTech Biopharmaceuticals is enjoying a higher profile now that the business community is paying more attention to rare disease treatments, said the company's CEO Tim Miller. Miller took the top job after his company Abeona Therapeutics was acquired by PlasmaTech earlier this month. Miller said Abeona was a good fit for PlasmaTech because of the increasing demand for gene therapy products. He said the company's treatment to treat the genetic metabolism disorder Sanfilippo syndrome will start Phase 1/2 trials later this year. Finally, Miller said the decision by George Soros' fund to take a 5% stake in the company earlier this month also increased the profile of the company.
Stocks in this video: PTBI
By Gregg Greenberg
Source: http://www.thestreet.com/video/13155309/rare-disease-drug-demand-soros-interest-raising-plasmatech-profile.html
With the global economy in the doldrums, and many people find themselves under-employed at best or unemplyed at worse, its time for people to take a serious look at the stock market as a viable arena to boost their finances.My blog offers useful insights into the market that will enable even a novice to cash in on Wall Street bonanza.....learn the secrets of the 1% who own 90% of nation's wealth. So welcome aboard the money train.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment